nach oben

Nuclear Medicine and Molecular Imaging

Erschienen in:

04.01.2019 | Perspective

Nuclear Medicine Theranostics: Perspective from Pakistan

verfasst von: Humayun Bashir, M. Numair Younis, M. Rehan Gul

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Nuclear medicine has been offering diagnostic and therapeutic solution since the introduction of radioactive iodine for thyroid diseases since decades. However, the concept of theranostics has given a new found impetus to the use of pairs of radiopharmaceuticals for diagnosis and treatment. Presented here is a perspective on theranostics from Pakistan.

Younis N, Bashir H. Theranostics–neuroendocrine tumours. J Cancer Allied Spec. 2018;4(2):1.

Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: the early history. Thyroid. 1997;7:163–76.CrossRefPubMed

Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics. 2016;36:258–78.CrossRefPubMed

Ahmadzahehfar H, Sabet A, Wilhelm K, Biersack HJ. Iodine-131-lipiodol therapy in hepatic tumours. Methods. 2011;55:246–52.CrossRef

Rizzieri D. Z. (ibritumomabtiuxetan) after more than a decade of treatment experience, what have we learned. Crit Rev OncolHematol. 2016;105:5–17.CrossRef

Handkiewicz-Junak D, Poeppel TD, Bodei L, Aktolun C, Ezziddin S, Giammarile F, et al. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. Eur J Nucl Med Mol Imaging. 2018;45:846–59.CrossRefPubMedPubMedCentral

Kunikowska J, Lewington V, Krolicki L. Optimizing somatostatin receptor imaging in patients with neuroendocrine tumors: the impact of 99mTc-HYNICTOC SPECT/SPECT/CT versus 68Ga-DOTATATE PET/CT upon clinical management. Clin Nucl Med. 2017;42:905–11.CrossRefPubMed

Ajit S. Rhenium 188: the poor Man’s yttrium. World J Nucl Med. 2017;16:1–2.CrossRef

Zaman MU, Fatima N, Sajjad Z, Hashmi I. High-dose I131 therapy on outpatient basis: imperative and no more a desire. Pak J Nucl Med. 2012;2:92–7.

10.

Memon AS, Laghari NA, Mangi FH, Hussain MM, Nohario SH. Isolation period of 131I administered patients at NIMRA Jamshoro Pakistan. Int J Radiol Radiat Ther. 2017;2:2–5.

11.

Hassan A, Siddique M, Bashir H, Riaz S, Wali R, Mahreen A, et al. 18F-FDG PET-CT imaging versus bone marrow biopsy in pediatric Hodgkin’s lymphoma: a quantitative assessment of marrow uptake and novel insights into clinical implications of marrow involvement. Eur J Nucl Med Mol Imaging. 2017;44:1198–206.CrossRefPubMed

12.

Riaz S, Bashir H, Niazi IK. Triage of limited versus extensive disease on F18 FDG PET/CT scan in small cell lung cancer Asia Ocean. J Nucl Med Biol. 2017;5:109–13.

13.

Riaz S, Bashir H, Hassan L, Jamshed A, Murtaza A, Hussain R. Impact and prognostic value of 18F FDG PET-CT scan in the evaluation of residual head and neck cancer - single centre experience from Pakistan. South Asian J Cancer. 2017;6:81–3.PubMedPubMedCentral

14.

Zaman MU, Fatima N, Zaman A, et al. Significantly low effective dose from 18FDG PET/CT scans using dose reducing strategies: “lesser is better”. Asian Pac J Cancer Prev. 2016;17:3465–8.PubMed

15.

Riaz S, Nawaz MK, Faruqui ZS, Kazmi AS, Loya A, et al. Diagnostic accuracy of 18F-FDG PET-CT in the evaluation of carcinoma of unknown primary. Mol Imaging Radionucl Ther. 2016;25:1–10.CrossRef

16.

Bodei L, Brand MJ, Baum RP, Pavel ME, Horsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.CrossRefPubMedPubMedCentral

17.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Chasen B, Mittra E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.CrossRefPubMedPubMedCentral

18.

Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 trial. J Clin Oncol. 2018;36:2578–84.CrossRefPubMedPubMedCentral

19.

Mittra ES. Neuroendocrine tumor therapy: 177Lu-DOTATATE. Am J Roentgenol. 2018;211:278–85.CrossRef

20.

Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:471–95.CrossRefPubMed

21.

Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33.CrossRefPubMed

22.

Gavan SP, Thompson AJ, Payne K. The economic case for precision medicine. Expert Rev Precis Med Drug Dev. 2018;3:1–9.CrossRefPubMedPubMedCentral

23.

Ajit S. An overview of nuclear medicine and PET CT in India. Curr Trends Clin Med Imaging. 2017;1(5).

24.

Atutornu J, Hayre CM. Personalized medicine and medical imaging: opportunities and challenges for contemporary health care. J Med Imaging Radiat Sci. 2018;49:352–9.CrossRefPubMed

Titel: Nuclear Medicine Theranostics: Perspective from Pakistan
verfasst von: Humayun Bashir
M. Numair Younis
M. Rehan Gul
Publikationsdatum: 04.01.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Nuclear Medicine and Molecular Imaging / Ausgabe 1/2019
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-018-00566-7

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Radiomics in Oncological PET/CT: a Methodological Overview

Nuclear Theranostics in Indonesia: Past, Present, and Future

Comparative Cardiac Phantom Study Using Tc-99m/I-123 and Tl-201/I-123 Tracers with Cadmium-Zinc-Telluride Detector-Based Single-Photon Emission Computed Tomography

The Emergence of Theranostics in the Philippines: Overcoming Challenges and Bringing Hope

Procedural Recommendations for Lymphoscintigraphy in the Diagnosis of Peripheral Lymphedema: the Genoa Protocol

Diagnostic Reference Levels for Adult Nuclear Medicine Imaging Established from the National Survey in Korea